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We show that the anti-human immunodeficiency virus agent, 3'-azido-3'-deoxythymidine (AZT), which
suppresses infectivity and cytopathic effects of human immunodeficiency virus, also effectively inhibits
Epstein-Barr virus (EBV) DNA replication. However, AZT has no effect on four other human herpesviruses:
cytomegalovirus, varicella-zoster virus, and herpes simplex virus types 1 and 2. The combination of acyclovir
and AZT, while it is not synergistic, has an additive effect against EBV replication. AZT may prove to be a
useful drug for treatment of coinfections with human immunodeficiency virus and EBV.
In recent years, we have shown that several nucleoside
analogs selectively inhibit the replication of Epstein-Barr
virus (EBV) (14-17). One drug has been tested in trials in
patients with infectious mononucleosis (6, 21; C. M. Van der
Horst, J. Joncas, G. Ahronheim, G. Stein, M. Gurwith, G.
Fleisher, J. L. Sullivan, J. Sixbey, C. Sumaya, R. Schooley,
S. Roland Sweezy, and J. S. Pagano, Program Abstr. 26th
Intersci. Conf. Antimicrob. Agents Chemother., abstr. no.
318, 1986). In searching for other antiherpetic agents, we
discovered that 3'-azido-3'-deoxythymidine (AZT), which is
active against human immunodeficiency virus (HIV) both in
vitro (20) and in vivo (26), strongly inhibits EBV replication.
Inhibition was surprisingly selective in that the drug showed
no detectable effect on replication of the other human
herpesviruses, cytomegalovirus (HCMV), varicella-zoster
virus (VZV), and herpes simplex virus types 1 and 2 (HSV-1
and HSV-2).
To test the effect of AZT on EBV DNA replication, we
used P3HR-1 (LS) cells, a high-virus-producer cell line de-
rived from P3HR-1 cells by gradual adaptation to growth in
low-serum medium (1.5% newborn calf serum) (12). Under
these conditions, approximately 20 to 50% of the cells are
spontaneously activated to produce virus and large numbers
of linear EBV DNA genomes (unpublished data). Exponen-
tially growing P3HR-1 (LS) cells were treated for 14 days
with various concentrations of AZT in RPMI 1640 medium
containing 1.5% serum. The cells were harvested, and EBV
genome copy numbers were determined by complementary
RNA-DNA hybridization with an EBV-specific cRNA probe.
Figure 1 shows the dose-dependent inhibition of EBV
genome replication by AZT. EBV genome copy numbers
decreased with increasing drug concentrations. The virus
50% effective dose (ED50) and ED90 were determined from
the semilogarithmic plot of drug concentrations against viral
genome copies per cell, assuming the residual genome level
(30 copies per cell) achieved by an effective drug concentra-
tion (100 ,uM) as zero and the viral genome level in the
drug-free control as 100. We have shown previously that the
residual EBV copy number of -30 per cell is due to episomal
forms which are insensitive to antiviral drugs (16). The ED50
and ED90 thus obtained were 3 and 30 ,uM, respectively. For
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comparison, in patients with acquired immunodeficiency
syndrome (AIDS) the plasma concentration of AZT reaches
levels of 6 to 10 ,uM 1 h after an intravenous dose of 5 mg/kg.
We considered that the EBV-inhibitory effect of AZT
could be the consequence of selective killing of the produc-
tive cells in P3HR-1 (LS) populations, and therefore, we
monitored cell growth and viability during drug treatment.
Cell growth was not significantly affected at drug concentra-
tions as high as 50 p.M. At 100 ,uM AZT, approximately 30%
growth inhibition was observed; however, the viability of the
cells remained the same as that of the control. These results
indicate that AZT at concentrations as high as 100 ,uM is
cytostatic but not cytotoxic.
Since all herpesviruses induce the formation of new viral
DNA polymerases, we thought that drugs inhibitory to EBV
might also inhibit HSV, VZV, and HCMV replication (13).
We therefore tested the effect of AZT on the replication of
these viruses by using plaque-reduction assays (3); 9-(1,3-
dihydroxy-2-propoxymethyl)guanine (DHPG) was used as a
positive drug control. As expected, DHPG exhibited potent
anti-HCMV, -HSV-1 and -HSV-2 activities, with ED50s
ranging from 0.05 to 1.5 puM (Table 1). Surprisingly, AZT
























FIG. 1. Dose-dependent inhibition of EBV genome replication
by AZT. Exponentially growing P3HR-1 (LS) cells were seeded at a
density of 106/ml and incubated in various concentrations of drugs
for 14 days. EBV genome copy numbers per cell represent the




TABLE 1. Effects of AZT and DHPG on herpes-group viruses
Virus ED50 (,uM)
(strain) DHPG AZT
HSV-1 (KOS) 0.05 >100
HSV-2 (333) 0.2 >100
HCMV (AD169) 1.5 >100
VZV (Oka) ND" >250
a ND, Not determined.
To assess whether the inhibitory effect of AZT on EBV
replication was reversible, we treated P3HR-1 (LS) cells
with 50 ,uM AZT for 14 days to reduce the viral genome copy
numbers down to the residual levels (30 copies per cell) and
then released the cells into drug-free medium. Figure 2
shows that the inhibitory effect was slowly reversed upon
removal of the drug. Replication of approximately 50% of
the viral genome numbers was recovered by 14 days after
drug removal. It required 21 days for the level of viral
genomes to be restored to the control level; this result is in
contrast to that obtained with acyclovir (ACV), the effect of
which was completely abolished 11 days after removal of the
drug (16). Slow kinetics of recovery have been demonstrated




Because patients with AIDS have toxic reactions to AZT,
combinations of drugs that are potentially synergistic and
would permit reduction of AZT dosage are being sought.
Synergistic inhibition of HIV replication in vitro by suramin
and ACV (22), by phosphonoformate and alpha-A-interferon
(11), and by ACV and AZT (19) has been reported, and a
combination AZT-ACV therapy in AIDS is being evaluated
clinically (S. Broder, personal communication). We looked
for evidence of a potentiating effect between AZT and ACV
on the replication of EBV but found only an additive effect
when the two drugs were used in combination in suboptimal
concentration (Table 2). The ED50 and ED90 of ACV alone
for EBV replication are 0.3 and 9 ,uM, respectively (16).
The mechanism of selective inhibition by AZT on EBV
replication is not understood. Initial preferential phosphor-
ylation in virus-infected cells is a prerequisite for selective
activity of several nucleoside analogs (for a review, see
reference 13). The monophosphorylated compounds are
converted by host cellular kinases to triphosphates, which,
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FIG. 2. Kinetics of inhibition and reversibility of EBV DNA
replication in P3HR-1 (LS) cells treated with AZT.
TABLE 2. Combined effects of AZT and ACV
on EBV replication
Concn of EBV genome copy no. at AZT concn (,uM)
ACV (,uM) 0 2.5 10
0 465 382 116
1 216 133 80
5 82 62 62
DNA polymerase (5). In HIV-infected cells, initial phos-
phorylation of AZT is carried out by cellular thymidine
kinase rather than viral enzyme, and the levels of AZT-
monophosphate measured in uninfected and infected cells
are similar (7). Thus, EBV-encoded thymidine kinase is
unlikely to be required for the selective inhibition of EBV
replication by AZT.
Of special interest are the findings that AZT has virtually
no effect on HCMV, VZV, and HSV-1 and HSV-2, despite
the fact that all herpesviruses encode novel DNA polymer-
ases that are quite distinct from cellular DNA polymerases
and which share unique biochemical properties such as
stimulation by high-salt concentrations in vitro. Moreover,
there is extensive conservation of sequence of herpesvirus
DNA polymerase genes (2). Indeed, in the predicted se-
quence ofEBV and HSV-1 polymerases, there is 45% homol-
ogy in the C-terminal two-thirds of the polypeptides (8). All of
the known antiherpetic drugs generally affect several of the
herpes-group viruses, although HCMV is insensitive to ACV
(18) and HSV-2 is insensitive to BVDU (4).
Since AZT-triphosphate is a potent inhibitor of HIV
reverse transcriptase (7), the question arises whether EBV
DNA polymerase shares with the reverse transcriptase some
common binding sites for the phosphorylated drug. If so,
these sites are not available in oa-polymerase, since AZT-
triphosphate has low affinity for this cellular enzyme (7). In
addition, treatment of EBV-infected cells with AZT may
cause a reduction in the intracellular level of dTTP, which is
a competing substrate for EBV DNA polymerase. This effect
would facilitate the binding of AZT-triphosphate to viral
polymerase. The structural characteristics of AZT with its
3'-azido group would also cause termination of DNA elon-
gation if the nucleoside moiety were incorporated into viral
DNA. In any case, the unique susceptibility of EBV to AZT
may provide a lead toward ascertaining active sites on HIV
reverse transcriptase for binding of the drug.
EBV has been suggested as one of the cofactors which
determine whether AIDS will result from infection by HIV
(9, 23). Since opportunistic viral infections, especially EBV
and HCMV, are prevalent in AIDS (1, 24) treatment of
symptomatic HIV infection with AZT may have an addi-
tional benefit in reducing possible facilitative effects or
complications resulting from reactivated or primary EBV
infection; however, this possibility has not yet been studied
directly. Although the combination of ACV and AZT is not
synergistic against EBV, neither is it antagonistic (25).
Whether the EBV-associated B-lymphocytic lymphomas
that are relatively common in AIDS would be affected is a
matter of speculation (10).
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